Bert Vogelstein
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (35)
Supplemental Figure 6. Correlation between the cfDNA derived from colon epithelial cells, lung cells, and pancreatic cells, and the fraction of cfDNA derived from neoplastic colon epithelial cells, lung cells, or pancreatic cells.
Year:
2025
Supplemental Figure 5. Methylation profiles using quadratic programming vs. non-negative least- squares regression using the reference matrix described in Moss et al. (43). Pearson’s correlation coefficient and p values are presented at the bottom of this figure, showing the derived contributions from each of the 25 tissue types that could be assessed.
Year:
2025
Supplementary Table 1. Demographic, clinical, and plasma cfDNA data for the patients included in the study deconvoluted by Sun et al. (3) and Moss et al. (43) by QP and NNLS. NA, not available. Supplementary Table 2. Demographic, clinical, and plasma cfDNA data for the patients included in the study deconvoluted by Loyfer et al. (44) NA, not available.
Year:
2025
Supplementary Notes 1-5. Supplementary Note 1: Origins of cell-free DNA. Supplementary Note 2: Leukocyte Lysis. Supplementary Note 3: Reference datasets and deconvolution algorithms used to interpret whole genome bisulfite sequencing data. Supplementary Note 4: Turnover rates. Supplementary Note 5: Relationships between ctDNA and tissue specific cfDNA in cancer patients.
Year:
2025
Supplemental Figure 2. The concentration of plasma cfDNA in previous described patients with cancer according to stage. (A) The concentration of cfDNA in patients of all cancer types (9). The concentration of cfDNA in patients with Stage III cancers was significantly higher than that of patients with Stage I cancers (p
Year:
2025
Supplemental Figure 10. In silico mixing experiments (N = 10) of buffy coat bisulfite sequencing data with liver (A), lung (B), colon epithelial cell (C), and left atrium (D) bisulfite sequencing data deconvoluted using the Moss et al. (43) reference matrix and quadratic programming shows excellent agreement between predicted and actual fractional contribution.
Year:
2025
Supplemental Figure 4. Methylation profiles using quadratic programming vs. non-negative least- squares regression using the reference matrix described in Sun et al. (3). Pearson’s correlation coefficient and p values are presented at the bottom of this figure, showing the derived contributions from each of the 12 tissue types that could be assessed.
Year:
2025
Supplementary Table S1: Cohorts for CSF-BAM components. Supplementary Table S2A: SafeBSeqS primer sequences. Supplementary Table S2B: SafeTseqS primer sequences. Supplementary Table S2C: Aneuploidy analysis primer sequences. Supplementary Table S2D: Mutation analysis primer sequences. Genomic coordinates refer to hg19. Supplementary Table S3: Summary of SafeBSeqS analysis in WBC control samples. Supplementary Table S4: Summary of CSF-BAM SafeBSeqS analysis in CSF. Supplementary Table S5: Summary of SafeTSeqS analysis in WBC control samples. Supplementary Table S6: Summary of CSF-BAM SafeTSeqS analysis in CSF. Supplementary Table S7: SafeBSeqS and SafeTSeqS analysis for CSF validation set 2. Supplementary Table S8: Summary of aneuploidy analysis in control samples. Supplementary Table S9: Summary of CSF-BAM aneuploidy analysis in CSF samples. Supplementary Table S10: Reproducibility of aneuploidy analysis. Supplementary Table S11: Comparison of aneuploidy analysis with CSF-BAM and Real-CSF. Supplementary Table S12: CSF-BAM mutation training set in non-cancer CSF samples. Supplementary Table S13: CSF-BAM mutation analysis in CSF samples. Supplementary Table S14: Demographic characteristics by sample. Supplementary Table S15: Diagnostic categories by sample. Supplementary Table S16: CSF-BAM results summary. Supplementary Table S17: CSF-BAM detection based on CSF reservoir abutment by sample. All samples with available clinical data are included. P-values were calculated by Fisher’s exact test. Supplementary Table S18A: TCR Clusters obtained via CSF-BAM. Supplementary Table S18B: TCR specificity annotation. Supplementary Table S19: CSF samples from patients with multiple sclerosis analyzed with SafeTSeqS and SafeBSeqS.
Year:
2025
Supplementary Figure S1. SafeBSeqS amplification. Supplementary Figure S2. SafeTSeqS amplification. Supplementary Figure S3. Aneuploidy reproducibility from two independent aliquots and libraries. Supplementary Figure S4. Metrics for targeted mutation panel. Supplementary Figure S5. Correlation of predicted aneuploidy neoplastic content to mutation neoplastic content. Supplementary Figure S6. A, TCR UIDs and B, BCR UIDS recovered for each CSF sample. Supplementary Figure S7. A, TCR clonality and B, BCR clonality for evaluable samples with total UIDs ≥20. Supplementary Figure S8. BCR clonality ROC and BCR IGHV4-34 gene segment usage. Supplementary Figure S9. Case reports demonstrating CSF-BAM clinical applicability.
Year:
2025
To explore how early cancers can be detected prior to clinical signs or symptoms, we assessed prospectively collected serial plasma samples from the Atherosclerosis Risk in Communities study, including 26 participants diagnosed with cancer and 26 matched controls. At the index time point, 8 of these 52 participants scored positively with a multicancer early detection test. All eight participants were diagnosed with cancer within 4 months after blood collection. In six of these eight participants, we were able to assess an earlier plasma sample collected 3.1 to 3.5 years prior to clinical diagnosis. In four of these six participants, the same mutations detected by the multicancer early detection test could be identified but at 8.6- to 79-fold lower mutant allele fractions. These results demonstrate that it is possible to detect ctDNA more than 3 years prior to clinical diagnosis and provide benchmark sensitivities required for this purpose. Significance: Earlier detection is a promising strategy to reduce cancer mortality. For cancers of all stages, therapies are more effective with a lower disease burden. In this study, we demonstrate that ctDNA is detectable 3 years or more before cancer diagnosis and provide estimates for the sensitivity required to achieve such very early detection. See related commentary by Crisafulli et al., p. 1774
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (31)
Peter A. Calabresi
-
Maria Popoli
Johns Hopkins University
Jarushka Naidoo
Honorary Senior Lecturer
Royal College of Surgeons in Ireland
Maximilian F Konig
Director, Cellular Therapy Program (Autoimmunity)
Johns Hopkins University School of Medicine
Christopher Douville
Assistant Professor
Johns Hopkins University School of Medicine
Anna E. Prizment
Faculty, Associate Professor
University of Minnesota
Joshua Cohen
Dana-Farber Cancer Institute
Kamel Lahouel
Assistant Professor
Translational Genomics Research Institute
Shibin Zhou
Professor
Johns Hopkins University School of Medicine
Kenneth Kinzler
Professor
Johns Hopkins University
Elizabeth Platz
Professor
Johns Hopkins University
Josef Coresh
Professor
Johns Hopkins University
Chetan Bettegowda
Johns Hopkins University School of Medicine
Haley Grant
Assistant Professor
University of Pittsburgh
Cristian Tomasetti
Professor
Beckman Research Institute, City of Hope
Debraj Mukherjee
Faculty
Johns Hopkins University School of Medicine
Carlos A Pardo
Professor
Johns Hopkins University School of Medicine
Carl Koschmann
University of Michigan Medical School
Yuk Ming Dennis Lo
Li Ka Shing Professor of Medicine
The Chinese University of Hong Kong (CUHK)
David Kamson
Johns Hopkins University
Corinne Joshu
Johns Hopkins University
Eric Jackson
Associate Professor of Neurosurgery
Johns Hopkins University School of Medicine
KC Allen Chan
Professor
The Chinese University of Hong Kong (CUHK)
Karisa Schreck
Assistant Professor
Johns Hopkins University School of Medicine
Matthias Holdhoff
Johns Hopkins University School of Medicine
Suman Paul
Johns Hopkins University
Brenda Diergaarde
University of Pittsburgh
Alireza Mansouri
Assistant Professor
Penn State
George Jallo
Johns Hopkins University
Cole Sterling
Assistant Professor
Johns Hopkins University
Drew Pardoll
Professor
Johns Hopkins University
Make your next move.
Prepare your application
Review drafts before you send them.